


CLAIMS:

136
-74-

1. A humanized antibody comprising the CDR from LO-CD2a.
2. The humanized antibody of Claim 1 which further contains in the framework of the light chain variable region of the humanized antibody, amino acids 9, 12, 41, 42, 50, 51 and 82 of the rat LO-CD2a light chain variable region as shown in Figure 31.
3. The humanized antibody of Claim 2 which further contains in the framework of the light chain variable region of the humanized antibody amino acids 47, 67, 70, 72, 76, 85, and 87 of the rat LO-CD2a heavy chain variable region as shown in Figure 33.
4. The humanized antibody of Claim 1 wherein the light chain variable region of the humanized antibody has the amino acid sequence of Figure 31.
5. The humanized antibody of Claim 4 wherein the heavy chain variable region of the humanized antibody has the amino acid sequence of Figure 33.
6. A process for inhibiting an immune response in a patient, comprising:
 - treating the patient with the antibody of Claim 1.
7. A process for inhibiting rejection of a graft in a patient, comprising:
 - treating a patient with the antibody of Claim 1.
8. A chimeric antibody which binds to the same epitope or a portion thereof on human lymphocytes as the monoclonal antibody produced by the cell line deposited as ATCC HB 11423, said chimeric antibody having a humanized constant region and a V_L chain having an amino acid sequence as shown in Figure 29 and a V_H chain having an amino acid sequence as shown in Figure 30.
9. A process for inhibiting an immune response in a patient, comprising:
 - treating the patient with the antibody of Claim 8.
10. A process for inhibiting rejection of a graft in a patient comprising:

137
-75-

treating a patient with the antibody of Claim 8.



add
ca } add
DB